Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer is a research paper published in Cells (2025). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH NCI awarded
Grant: R01-CA251361
NIH NCI awarded
Grant: P30-CA046934
National Institutes of Health
Grant: 5R01CA251361-05
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.
National Institutes of Health
Grant: 1R01CA251361-01
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.
National Institutes of Health
Grant: 3P30CA046934-20S2
Cancer Center Support Grant
Fields of Study
Keywords